Apimeds Pharmaceuticals US (APUS) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MetaVia is the larger company by market cap ($9.7 million vs $8.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | APUS | MTVA |
|---|---|---|
| Share price | $5.86 | $1.48 |
| Market cap | $8.84M | $9.72M |
| 1-day change | -16.88% | +1.03% |
| YTD return | -57.01% | — |
| 1-year return | -58.77% | — |
| EPS (TTM) | $-36.03 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $14.85 |
| 52-week low | $1.51 | $0.966 |
| Distance from 52-week high | -90.18% | -90.07% |
| Average volume | 3.65M | 230.88K |
| Shares outstanding | 1.51M | 6.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
APUS vs MTVA FAQ
Which is bigger, Apimeds Pharmaceuticals US or MetaVia?
MetaVia (MTVA) is larger, with a market capitalization of $9.72M compared with $8.84M for Apimeds Pharmaceuticals US (APUS).
Are Apimeds Pharmaceuticals US and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.